Galderma Group AG
🇨🇭Switzerland
Safety and Efficacy of CD10367 in Psoriasis Vulgaris
Phase 2
Completed
- Conditions
- Psoriasis Vulgaris
- Interventions
- Drug: CD10367 1% Solution - Non-desquamated zoneDrug: CD10367 3% Solution - Non-desquamated zoneDrug: CD10367 solution placebo - Non-desquamated zoneDrug: Betneval ointment - Non-desquamated zoneDrug: CD10367 3% Solution - Desquamated zoneDrug: CD10367 solution placebo - Desquamated zone
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 24
- Registration Number
- NCT03025282
- Locations
- 🇫🇷
Galderma Investigational Site, Nice, France
Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds
Not Applicable
Completed
- Conditions
- Nasolabial Folds in Chinese Population
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 175
- Registration Number
- NCT03003130
- Locations
- 🇨🇳
Q-Med AB, Shanghai, China
Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 61
- Registration Number
- NCT02995473
- Locations
- 🇨🇳
Galderma Investigational Site, Lincuo, Taoyuan, Taiwan
🇨🇳Galderma investigational site, Tainan, Taiwan
🇨🇳Galderma investigational site 1, Taipei, Taiwan
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT02932267
- Locations
- 🇺🇸
Dermresearch, Austin, Texas, United States
🇸🇬CIDP, Singapore, Singapore
Pain and Safety of Restylane With and Without Lidocaine for Correction of Moderate and Severe Nasolabial Folds
Not Applicable
Completed
- Conditions
- Nasolabial Fold
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2023-06-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 70
- Registration Number
- NCT02918721
- Locations
- 🇨🇳
Q-Med AB, Shanghai, China
A Treatment for Severe Inflammatory Acne Subjects
Phase 4
Completed
- Conditions
- Acne Vulgaris
- Interventions
- First Posted Date
- 2016-09-13
- Last Posted Date
- 2022-12-09
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 186
- Registration Number
- NCT02899000
- Locations
- 🇺🇸
Galderma Laboratories, LP, Fort Worth, Texas, United States
A Clinical Trial to Evaluate the Efficacy of Two Acne Treatments
- First Posted Date
- 2016-04-29
- Last Posted Date
- 2023-12-28
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 127
- Registration Number
- NCT02755545
- Locations
- 🇺🇸
Stephens & Associates, Inc. Texas Research Center, Richardson, Texas, United States
Adapalene 0.3% - Benzoyl Peroxide 2.5% Gel and Risk of Formation of Atrophic Acne Scars
Phase 4
Completed
- Conditions
- Acne VulgarisAtrophic Acne Scars
- Interventions
- Drug: ABPO Forte GelDrug: Vehicle gel
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2022-09-14
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 67
- Registration Number
- NCT02735421
Comparison of Dysport Reconstitution at 1.5 mL and 2.5 mL for the Treatment of Moderate to Severe Glabellar Lines
Phase 4
Completed
- Conditions
- Glabellar LinesWrinkles
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 60
- Registration Number
- NCT02718118
- Locations
- 🇺🇸
AboutSkin Dermatology and DermSurgery, Greenwood Village, Colorado, United States
🇺🇸Skin Research Institute, Coral Gables, Florida, United States
🇺🇸Marina Peredo, MD, PC, Smithtown, New York, United States
Emervel for the Correction of Lower Face Wrinkles & Folds
Phase 4
Completed
- Conditions
- Nasolabial FoldsWrinklesMarionette Lines
- First Posted Date
- 2016-03-24
- Last Posted Date
- 2022-08-01
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 30
- Registration Number
- NCT02718040